ArticleScientific reports2026
Short term real-world effectiveness of faricimab in neovascular age-related macular degeneration patients in the Republic of Korea.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To analyze visual and anatomic outcomes of faricimab injection in neovascular age-related macular degeneration (nAMD) in a real-world setting in Korea. We collected data from nAMD patients who received faricimab injection from 2024 to 2025. The past injection history, and faricimab injection history was obtained. Visual acuity (VA) and central macular thickness (CMT) outcomes for 1, 3, 6, 12 months after initial faricimab injection were compared to baseline, and also compared between sex, different age-groups, and naïve vs. non-naïve groups. A total of 286 patients, 293 eyes from 8 university hospitals were included in this study. VA improved from baseline 58.9 ± 17.1 letters to 60.7 ± 23.5, 61.0 ± 18.1, 59.9 ± 19.3, 60.5 ± 18.2 letters at 1, 3, 6, 12 months respectively (statistically significant at 3 months, p = 0.009), while CMT improved by -60.6 ± 89.0, -55.9 ± 87.3, -46.5 ± 97.5, -70.7 ± 97.8 μm compared to baseline (p < 0.001 at all timepoints). An age group analysis showed that the youngest age group (< 60 years) had superior VA results, while the naïve group showed superior outcomes compared to the non-naïve group. CMT fluctuation showed inverse correlation with visual acuity at 6 months, with lower CMT fluctuation being associated with the young and naïve. Faricimab injection for nAMD, in a real-world setting in the Republic of Korea, showed significant functional and anatomic improvements with superior results in the younger age group and naïve group, suggesting promising effectiveness of a bispecific blockage of VEGF-A and Ang-2 at the initial phases of nAMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.